secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001193125-25-053473
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Q4 net loss from continuing ops $15.7M; cash extends into Q1 2026; SER-155 advances
--------------------------------------------------------------------------------

- Net loss from continuing ops: FY2024 $125.8M vs $190.1M in 2023; Q4 $15.7M vs $34.7M.
- R&D expenses fell to $64.6M (FY2024) from $117.6M; focus on lead program SER-155.
- Cash $30.8M at Dec 31; plus $50M received Jan 2025, expects funding into Q1 2026.
- SER-155: FDA supports BSI reduction at day 30 as Phase 2 endpoint; draft protocol in Q2 2025.
- Expecting $25M Nestlé installment in July 2025; VOWST sale yields up to $275M in milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525053473/0001193125-25-053473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525053473/d914751d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-053473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer